Breast Neoplasms: Clinical Trials

14,436 trials for Breast Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6806 completed, 2050 unknown, 2022 recruiting, 1270 terminated. 4151 Not applicable, 3992 Phase 2, 2200 Phase 1, 1349 Phase 3, 285 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable4151Completed 2035, Recruiting 615, Unknown 576, Active not recruiting 297, Not yet recruiting 252, Terminated 205, Withdrawn 130, Enrolling by invitation 29, Suspended 12
Phase 23992Completed 1681, Terminated 597, Recruiting 539, Unknown 522, Active not recruiting 283, Not yet recruiting 188, Withdrawn 166, Enrolling by invitation 9, Suspended 7
Phase 12200Completed 1061, Terminated 327, Recruiting 302, Active not recruiting 174, Unknown 165, Withdrawn 93, Not yet recruiting 58, Suspended 13, Enrolling by invitation 7
Phase 31349Completed 658, Unknown 188, Recruiting 163, Active not recruiting 137, Terminated 110, Not yet recruiting 55, Withdrawn 29, Suspended 7, Enrolling by invitation 2
Phase 4285Completed 136, Unknown 60, Recruiting 34, Not yet recruiting 20, Terminated 18, Withdrawn 10, Active not recruiting 7
Early Phase 1201Completed 103, Recruiting 26, Unknown 23, Withdrawn 20, Terminated 18, Not yet recruiting 5, Active not recruiting 4, Enrolling by invitation 2

Follow Breast Neoplasms: new trials by email Literature Review of Breast Neoplasms trials Research Report on Breast Neoplasms

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Feasibility Trial of a Culturally Tailored Resilience Intervention for Underserved Breast Cancer Survivors
BRIGHT Resilience Intervention, BRIGHT Survivorship Resource Booklet - Breast Cancer, Cancer Survivorship
Not applicableNot yet recruitingUniversity College Dublin802029-10-012026-11-12
Application of Multimodal MRI-based Radiomics in Histological Grading and Prognostic Assessment of Breast Cancer
DCE-MRI - Breast Cancer, Breast Cancer With Low to Intermediate HER2 Expression
Not yet recruitingHao Xu4002028-01-012026-02-05
Gut Microbiome Changes During Abemaciclib Therapy in Breast Cancer
Resistant Potato Starch, Placebo control - Breast Cancer, HER-2 Positive Breast Cancer
Not applicableNot yet recruitingUniversity of Vermont Medical Center122027-10-012026-02-12
DESIR. Evaluation of the Pre-therapeutic Activity of Dihydropyrimidine dEShydrogenase (DPD) in Patients With Cancer and/or Renal Failure
blood sampling, Blood sampling - Renal Impairment, Digestive Cancers
Not yet recruitingCentre Hospitalier Universitaire de Besancon7422027-10-012026-11-02
Developing and Testing the Efficacy of AI-Chatbot-Based
AIAI-Chatbot CalmMindRecoveryJourney delivering BMS-MC therapy - Breast Cancer
Not applicableNot yet recruitingNational Taiwan University Hospital682027-08-012026-08-27
EmpowerHer: Hybrid Digital Intervention for Breast Cancer Survivors
EmpowerHer Hybrid Program - Breast Cancer, Cancer Survivors
Not applicableNot yet recruitingUniversity of Valencia1472027-07-012026-06-30
Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer
Neratinib + endocrine therapy, Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, CDK4/6 + Endocrine therapy - Metastatic Invasive Breast Cancer, Resistant Breast Cancer
Phase 2Not yet recruitingUniversity of California, San Diego1502027-07-012026-07-27
Internal Mammary Node Irradiation After Neoadjuvant Systemic Therapy for Breast Cancer
Locoregional Radiotherapy With Internal Mammary Node Irradiation, Locoregional Radiotherapy Without Internal Mammary Node Irradiation - Breast Neoplasms
Phase 3Not yet recruitingMahidol University17602027-07-012026-11-13
Korea Post Marketing Surveillance (PMS) Study of Talzenna®
Talzenna - Breast Neoplasms
WithdrawnPfizer2027-06-012026-09-14
HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry.
Gemcitabine (1000 mg/m^2), Paclitaxel 80 mg/m2 weekly - Triple Negative Breast Cancer, Metastatic Triple-negative Breast Cancer
Phase 2Not yet recruitingThe University of The West Indies7502027-06-012026-09-22
A Master Trial Assessing the Technical Feasibility of First-In-Human Real-Time Image Guided Radiation Therapy Methods
Real-Time Image Guided Radio Therapy (IGRT) - Cancer
Not applicableNot yet recruitingUniversity of Sydney402027-06-012026-05-20
Molecular Breast Imaging (MBI)-Guided Biopsy
Molecular Breast Imaging, MBI-guided biopsy - Breast Cancer Detection, Breast Neoplasm
Not applicableNot yet recruitingSmart Breast Corp.2502027-06-012025-08-11
Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)
[18F]FMISO-PET with contrast-enhanced MRI - Triple Negative Breast Cancer
Early Phase 1RecruitingUniversity of Alabama at Birmingham202027-06-012026-08-17
Multi-4SCAR-T Therapy Targeting Breast Cancer
4SCAR T cells - Breast Cancer
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute1002027-06-012026-11-02
Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and First Diagnosis of Brain Metastases (HERBRAIN)
SRS/fSRT+T-Dxd - Breast Cancer (Advanced/Metastatic)
Phase 2Not yet recruitingAzienda Ospedaliero-Universitaria Careggi602027-05-152026-10-29
Early Intervention
Juzo Compression Sleeve and Glove, Compression Sleeve Sensor - Breast Cancer, Breast Cancer Treatment Related Lymphedema
Not applicableNot yet recruitingMassachusetts General Hospital402027-05-012026-07-13
Cancer Awareness Among Syrian Migrants
PMT-Based Cancer Screening Educational Intervention, PMT-Based Cancer Screening Education Program - Breast Cancer Screening, Cervical Cancer Screening
Not applicableNot yet recruitingToros University302027-03-092026-10-15
TROPION Breast Respond in 1L TNBC
Dato-DXd - Unresectable Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer
Not yet recruitingDaiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company4002027-03-012026-10-09
Semaglutide for Weight Management During Hormone Therapy for Early Breast Cancer
Semaglutide (Wegovy®) - Breast Cancer (Early Breast Cancer), Obesity
Phase 2Not yet recruitingAarhus University Hospital322027-03-012026-11-02
Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced Breast Cancer
Apatinib mesylate, Physician's choice chemotherapy - Breast Neoplasms, Advanced Breast Cancer
Phase 2Not yet recruitingYunnan Cancer Hospital562027-03-012026-10-30

Showing 20 of 14436. Sign in to see all of them.

Narrower conditions

Triple Negative Breast Neoplasms (1202)  ·  Neoplasms (770)  ·  Ovarian Neoplasms (698)  ·  Colorectal Neoplasms (607)  ·  Lung Neoplasms (605)  ·  Neoplasm Metastasis (605)  ·  Prostatic Neoplasms (570)  ·  Carcinoma, Non-Small-Cell Lung (554)  ·  Pancreatic Neoplasms (393)  ·  Melanoma (372)  ·  Stomach Neoplasms (370)  ·  Colonic Neoplasms (338)  ·  Motor Activity (298)  ·  Breast Neoplasms, Male (286)

Broader conditions

Skin and Connective Tissue Diseases (14436)  ·  Skin Diseases (14422)  ·  Neoplasms by Site (14407)  ·  Breast Diseases (14345)  ·  Neoplasms (13666)  ·  Pathological Conditions, Signs and Symptoms (2043)  ·  Urogenital Diseases (1543)  ·  Neoplasms by Histologic Type (1518)  ·  Urogenital Neoplasms (1453)  ·  Genital Diseases (1385)  ·  Pathologic Processes (1381)  ·  Digestive System Diseases (1306)  ·  Digestive System Neoplasms (1275)  ·  Female Urogenital Diseases and Pregnancy Complications (1235)  ·  Female Urogenital Diseases (1227)

Interventions

Paclitaxel (654)  ·  Trastuzumab (650)  ·  Cyclophosphamide (620)  ·  Docetaxel (511)  ·  Capecitabine (451)  ·  Letrozole (391)  ·  Carboplatin (364)  ·  Fulvestrant (346)  ·  Doxorubicin (328)  ·  Tamoxifen (283)  ·  pembrolizumab (273)  ·  Anastrozole (251)  ·  Epirubicin (238)  ·  exemestane (233)  ·  Radiotherapy (226)

Sponsors

National Cancer Institute (NCI) (308)  ·  Fudan University (260)  ·  M.D. Anderson Cancer Center (243)  ·  Memorial Sloan Kettering Cancer Center (240)  ·  AstraZeneca (183)  ·  Hoffmann-La Roche (183)  ·  Novartis Pharmaceuticals (181)  ·  Pfizer (161)  ·  Mayo Clinic (152)  ·  Dana-Farber Cancer Institute (143)  ·  Alliance for Clinical Trials in Oncology (93)  ·  Eli Lilly and Company (93)  ·  City of Hope Medical Center (90)  ·  Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (89)  ·  Washington University School of Medicine (88)

Countries

United States (6239)  ·  China (1772)  ·  France (1222)  ·  Spain (944)  ·  Canada (924)  ·  Italy (884)  ·  United Kingdom (771)  ·  Germany (683)  ·  South Korea (608)  ·  Belgium (568)  ·  Australia (446)  ·  Taiwan (395)  ·  Netherlands (393)  ·  Turkey (Türkiye) (384)  ·  Brazil (344)

Top investigators

Norman Wolmark, MD (36)  ·  Edith A. Perez, MD (18)  ·  Biyun Wang, Professor (15)

Results publications

PMID 38979716, PMID 34037241, PMID 29522361, PMID 32450725, PMID 40443562, PMID 39606939, PMID 40207789, PMID 41170811, PMID 22508812, PMID 24529560, PMID 32101663, PMID 33084020, PMID 39024777, PMID 42334791, PMID 18355913, PMID 22649152, PMID 25071111, PMID 26101239, PMID 26348120, PMID 26438146, PMID 27432417, PMID 28898379, PMID 30032196, PMID 30207593, PMID 30711522, PMID 32379297, PMID 33307491, PMID 34252375, PMID 35594464, PMID 39613746, PMID 40421669, PMID 12393820, PMID 15894097, PMID 19903919, PMID 20299316, PMID 21247627, PMID 21376385, PMID 21796368, PMID 21880792, PMID 22198468, PMID 23871490, PMID 23902874, PMID 24091623, PMID 24682463, PMID 24881463, PMID 25092775, PMID 25439688, PMID 27367583, PMID 28057664, PMID 29141853

NIH funding

2023 (99), 2016 (67), 2019 (57), 2014 (54), 2017 (54), 2025 (53), P30CA033572 (52), 2018 (49), 2015 (46), 2008 (37), P30CA015083 (36), 2009 (34), 2005 (32), P30CA016672 (30), P30CA043703 (30)